| payload |
{"created_at":"2026-04-16T02:08:52.472 {"created_at":"2026-04-16T02:08:52.472606+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:89bfd72e5afd8a0f","evidence_event_ids":["evt_ed574ed99830"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt","article_chars":2309,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_83c1faaae2ce40ec","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:47:59.272620+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt","source_event_id":"evt_ed574ed99830","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"fcf612b4786653f2","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-15","2026-04-13","2026-04-14","2026-02-04","2026-02-03","2013-02-20","2008-06-25","2026-04-16T02:08:52.472606+00:00"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"person","name":"Christopher R. Cline","relevance":"high","symbol":"","type":"reporting-owner_officer"},{"asset_class":"broker","name":"Morgan Stanley Smith Barney LLC","relevance":"medium","symbol":"","type":"broker"}],"event_type":"listing","information_gaps":["The cleaned text does not explicitly label each transaction line as 'sale' vs 'disposition' vs 'shares held'\u2014it only shows numeric fields and dates.","The filing\u2019s stated purpose (e.g., number of shares to be sold under Rule 144) is not clearly extracted in the provided text.","No explicit total shares to be sold or aggregate sale amount is clearly summarized in the provided excerpt.","The signal mentions 'TVTX filed 144', but the excerpt does not explicitly state the ticker symbol; TVTX is inferred only from the signal context, not from the filing text shown."],"key_facts":["SEC accession number: 0001950047-26-003478.","Form type: 144 (filed as of date 2026-04-15; date of change 2026-04-15).","Subject company: Travere Therapeutics, Inc. (CIK 0001438533; SIC 2834).","Reporting owner: Christopher R. Cline (officer; mail address c/o Travere Therapeutics, Inc.).","The document includes multiple transaction lines for Christopher Cline with dates in 2026 (e.g., 04/13/2026, 04/14/2026, 04/15/2026) and share/price/amount figures (e.g., 43206.54; 92241550; 369.63; 303522.58; 1875.25; 56165.62; 232616.03).","Broker listed: Morgan Stanley Smith Barney LLC (address shown in the filing)."],"numeric_claims":[{"label":"Form 144 filed as of date","value":"2026-04-15"},{"label":"SEC accession number","value":"0001950047-26-003478"},{"label":"CIK (Travere Therapeutics, Inc.)","value":"0001438533"},{"label":"Transaction date examples (from filing lines)","value":"04/13/2026, 04/14/2026, 04/15/2026"},{"label":"Example price/amount figures shown","value":"43206.54; 92241550; 369.63; 303522.58; 1875.25; 56165.62; 232616.03"}],"primary_claim":"On 2026-04-15, Travere Therapeutics, Inc. filed SEC Form 144 for transactions by officer Christopher R. Cline involving Travere common stock.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Travere Therapeutics, Inc. (TVTX) filed a Form 144 on 2026-04-15. The filing is associated with officer Christopher R. Cline and includes reported sales/transactions of common stock at specified dates and prices/amounts.","topics":["SEC Form 144","insider transactions","common stock","Travere Therapeutics","Christopher Cline"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260415","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003478.txt"}}... |